IP Library Granted Patent US 11,261,460
Granted Patent B2
US 11,261,460 · App. 14/994,477 · Granted Mar 1, 2022

Compositions and methods for treating diseases

Inventors: Barry John Byrne (Gainesville, FL); Darin J. Falk (Gainesville, FL); Christina Pacak (Gainesville, FL); Lara Robert DeRuisseau (Syracuse, NY); Cathryn Mah (Irvine, CA); David D. Fuller (Gainesville, FL)
Assignee: University of Florida Research Foundation, Incorporated
C12N15/86A61K9/0019A61K45/06A61K48/0058C12N7/00C12Y302/0102A61K48/0075C12N2710/16644C12N2750/14143C12N2750/14145C12N2750/14151C12N2810/6027C12N2830/008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,261,460
App. No.
14/994,477
Granted
Mar 1, 2022
Kind
B2
Abstract

The present invention provides compositions and methods of use pertaining to rAAV-mediated delivery of therapeutically effective molecules for treatment of diseases such as Pompe disease. These compositions in combination with various routes and methods of administration result in targeted expression of therapeutic molecules in specific organs, tissues and cells.

Claims (9)

1. A method of treating Pompe disease in a human patient having Pompe disease, said method comprising administering to said patient a therapeutically effective amount of a pseudotyped recombinant adeno-associated virus (rAAV) rAAV2/9, wherein said pseudotyped rAAV comprises a nucleic acid encoding a human alpha-glucosidase (GAA) polypeptide operably linked to a promoter,

wherein said promoter mediates expression of said GAA polypeptide in a muscle cell, wherein said promoter is selected from a desmin promoter and a creatine kinase promoter.

2. The method of claim 1 , said method comprising administering said pseudotyped rAAV to said patient intravenously.

3. The method of claim 1 , said method comprising administering said pseudotyped rAAV to said patient intramuscularly.

4. The method of claim 3 , said method comprising administering said pseudotyped rAAV directly to an intrathoracic muscle in said patient.

5. The method of claim 4 , wherein said intrathoracic muscle is myocardial tissue.

6. The method of claim 1 , wherein said pseudotyped rAAV is administered directly to the diaphragm of said patient.

7. The method of claim 1 , wherein said promoter is a desmin promoter.

8. The method of claim 1 , wherein said promoter is a muscle creatine kinase promoter.

Assignments (3)
CONFIRMATORY LICENSE Recorded Nov 21, 2022
From: UNIVERSITY OF FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061974/0815 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2016
From: BYRNE, BARRY JOHN; FALK, DARIN J.; PACAK, CHRISTINA; DERUISSEAU, LARA ROBERT; MAH, CATHRYN; FULLER, DAVID D.
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 040759/0598 →
CONFIRMATORY LICENSE Recorded Oct 3, 2016
From: UNIVERSITY OF FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040204/0415 →
Continuity (5)
Continuation 13527350 · Jun 19, 2012
Continuation In Part 12305869
Provisional Application 60891369 · Feb 23, 2007
Related Publication 20160369297A1 · Dec 22, 2016
Related Publication 20180051299A9 · Feb 22, 2018
Cited By (2)
US 12,220,245 US 12,642,484